Treatment of Inflammmation by Purified Human Proteinase Inhibitor.

用纯化的人蛋白酶抑制剂治疗炎症。

基本信息

  • 批准号:
    63570430
  • 负责人:
  • 金额:
    $ 1.28万
  • 依托单位:
  • 依托单位国家:
    日本
  • 项目类别:
    Grant-in-Aid for General Scientific Research (C)
  • 财政年份:
    1988
  • 资助国家:
    日本
  • 起止时间:
    1988 至 1990
  • 项目状态:
    已结题

项目摘要

Inhibitory activity of plasma on thermolysin, a bacterial proteinase inhibitor, was significantly higher in patients with Idiopathic Nephrotic Syndrome (INS) at relapse than in those in remission, chance proteinuria and/or hematuria and control subjecets. Sephadex G-200 gel-chromatography of plasma revealed the thermolysin inhibitory activity confined in the large molecular fractions, and Sephacryl S-300 chromatography, performed to purify alpha2-macroglobulin ( alpha2-MU) from human plasma, demonstrated the coincidence of the thermolysin inhibitory acitivity with alpha2-MU. These results suggest that the increased thermolysin ihnibitory activity of nephrotic plasma alpha2-MU contributes as a defense against possible invasion pathogens by inactivating proteinases elaborated by these organisms.alpha2-MU was examined for deposition in kidney tissue, using FITC-labelled anti-human alpha2-MU antibody (goat). A four-year-old male, exhibiting steroid refractory nephrotic syndrome, was found … More to have diffuse deposition of alpha2-MU in the glomeruli which showed diffuse mesangial proliferation and partial hyalinizati on by light microscopy. Administration of Camostat mesillate, a commercially available synthetic proteinase inhibitor, was started and he responded well to the therapy. Granular deposition of alpha2-MU was demonstrated in the mesangium of mice after the intraperitoneal injection of alpha2-MU. The deposition of alpha2-MU in the glomeruli may directly suggest the participation of proteinase (s) and proteinase inhibitor (s) in the inflammatory processes.In INS, proteinase inhibitory activity was significantly decreased when calculated per one mole of alpha2-MU, implicating a reduced proteinase inhibiting capacity of alpha2MU. The decreased proteinase inhibiting capacity of alpha2-MU was significantly associated with the inhibitory activity of plas ma on normal lymphocyte blastogenesis. Purified alpha2-MU complexed with chymotrypsin, intensively inhibited normal lymphocyte blastogenesis, induced by Concanavalin A, as compared to free alpha2-MU. Vascular permeability induced by nephrotic plasma was slightly ameliorated by the administration of purified alpha2-MU. Less
特发性肾病综合征(INS)复发患者血浆对嗜热菌蛋白酶(一种细菌蛋白酶抑制剂)的抑制活性显著高于缓解期、偶发性蛋白尿和/或血尿患者及对照组。SephadexG-200凝胶层析显示嗜热菌蛋白酶抑制活性局限于大分子组分,SephacrylS-300层析从人血浆中纯化α 2-巨球蛋白(α 2-MU),证明嗜热菌蛋白酶抑制活性与α 2-MU一致。这些结果表明,增加嗜热菌蛋白酶抑制活性的肾病血浆α 2-MU有助于作为一种防御可能的入侵病原体通过灭活蛋白酶阐述了这些有机体。α 2-MU的沉积在肾组织中进行了检查,使用FITC标记的抗人α 2-MU抗体(山羊)。一个四岁的男性,表现为类固醇难治性肾病综合征,被发现 ...更多信息 光镜下可见肾小球内α 2-MU弥漫性沉积,表现为弥漫性系膜增生和部分玻璃样变。开始给予卡莫司他甲磺酸盐(一种市售合成蛋白酶抑制剂),患者对治疗反应良好。在腹膜内注射α 2-MU后,在小鼠的系膜中证实了α 2-MU的颗粒沉积。α 2-MU在肾小球中的沉积可能直接表明蛋白酶和蛋白酶抑制剂参与炎症过程,在INS中,当计算每摩尔α 2-MU时,蛋白酶抑制活性显著降低,暗示α 2-MU的蛋白酶抑制能力降低。α_2-MU蛋白酶抑制能力的降低与血浆对正常淋巴细胞母细胞生成的抑制活性显著相关。与游离α 2-MU相比,纯化α 2-MU与胰凝乳蛋白酶复合,强烈抑制伴刀豆球蛋白A诱导的正常淋巴细胞胚细胞生成。通过施用纯化的α 2-MU,肾病血浆诱导的血管通透性略有改善。少

项目成果

期刊论文数量(21)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
浅見直: 日本小児科学会雑誌. 92. 1091-1094 (1988)
Asami Nao:日本儿科学会杂志 92. 1091-1094 (1988)。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
浅見 直,西原 亨,中野 徳,堺 薫: "賢疾患における血漿中非複合体型α2ーmacrogloblinによるプロテア-ゼインヒビタ-活性の検討" 日本小児科学会雑誌. 92. 1091-1094 (1988)
Nao Asami、Toru Nishihara、Toru Nakano、Kaoru Sakai:“疾病患者血浆中未复合的 α2-巨球蛋白的蛋白酶抑制剂活性检查”日本儿科学会杂志 92. 1091-1094 (1988)。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
浅見 直,西原 亨,林 三樹夫,堺 薫: "血中α1ーantichymotrypsin活性測定法の基礎的検討と賢疾患における変動の意義" 日本小児科学会雑誌. 92. 1889-1893 (1988)
Nao Asami、Toru Nishihara、Mikio Hayashi、Kaoru Sakai:“血液 α1-抗胰凝乳蛋白酶活性测量方法的基础研究及其波动对感官疾病的意义”日本儿科学会杂志 92。1889-1893(1988)。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
浅見直: 日本小児科学会雑誌. 92. 1087-1091 (1988)
Asami Nao:日本儿科学会杂志 92. 1087-1091 (1988)。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
浅見直: 日本腎臓学会雑誌. 31. 301-308 (1989)
Asami Nao:日本肾病学会杂志 31. 301-308 (1989)。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ASAMI Tadashi其他文献

ASAMI Tadashi的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ASAMI Tadashi', 18)}}的其他基金

EFFECT OF TREATMENT OF INFANTS WITH BORDER-LINE CONGENITAL HYPOTHYROIDISM ON THEIR LATER THYROID FUNCTIONS
边缘性先天性甲状腺功能减退症婴儿的治疗对其后期甲状腺功能的影响
  • 批准号:
    15591093
  • 财政年份:
    2003
  • 资助金额:
    $ 1.28万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Study on the risk of patiens with familial hypercholesterolemia by the determination of apolipoprotein E phenotyping
载脂蛋白E表型测定对家族性高胆固醇血症患者的风险研究
  • 批准号:
    07670845
  • 财政年份:
    1995
  • 资助金额:
    $ 1.28万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)

相似海外基金

Elucidation of the mechanism of rituximab-induced long-term remission in childhood nephrotic syndrome
阐明利妥昔单抗诱导儿童肾病综合征长期缓解的机制
  • 批准号:
    23H02926
  • 财政年份:
    2023
  • 资助金额:
    $ 1.28万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Severity analysis of minimal change nephrotic syndrome by multifaceted assessment of mitochondrial dysfunction
通过线粒体功能障碍的多方面评估来分析微小病变肾病综合征的严重程度
  • 批准号:
    23K15257
  • 财政年份:
    2023
  • 资助金额:
    $ 1.28万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Insight into Nephrotic Syndrome: Investigating Genes, Health, and Therapeutics
深入了解肾病综合征:研究基因、健康和治疗
  • 批准号:
    479884
  • 财政年份:
    2023
  • 资助金额:
    $ 1.28万
  • 项目类别:
    Operating Grants
REGULATORS OF CALCINEURIN PATHWAYS AS DIAGNOSTIC AND THERAPEUTIC TARGETS FOR NEPHROTIC SYNDROME
钙调磷酸酶途径的调节剂作为肾病综合征的诊断和治疗目标
  • 批准号:
    10560239
  • 财政年份:
    2023
  • 资助金额:
    $ 1.28万
  • 项目类别:
Pathogenesis of idiopathic nephrotic syndrome: defining the role of B cells and autoantibodies reactive to podocyte proteins
特发性肾病综合征的发病机制:定义 B 细胞和足细胞蛋白反应性自身抗体的作用
  • 批准号:
    487849
  • 财政年份:
    2023
  • 资助金额:
    $ 1.28万
  • 项目类别:
    Operating Grants
Insight Into Nephrotic Syndrome: Investigating Genes, Health, and Therapeutics
深入了解肾病综合征:研究基因、健康和治疗
  • 批准号:
    477325
  • 财政年份:
    2022
  • 资助金额:
    $ 1.28万
  • 项目类别:
    Operating Grants
A Pilot Study of Transcutaneous Auricular Vagus Nerve Stimulation for the Treatment of Idiopathic Nephrotic Syndrome in Children
经皮耳迷走神经刺激治疗儿童特发性肾病综合征的初步研究
  • 批准号:
    10516390
  • 财政年份:
    2022
  • 资助金额:
    $ 1.28万
  • 项目类别:
Clinical application of diagnostic method for idiopathic nephrotic syndrome utilizing podocyte cell biology
足细胞生物学诊断特发性肾病综合征的临床应用
  • 批准号:
    22K08324
  • 财政年份:
    2022
  • 资助金额:
    $ 1.28万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Exploring APOL1 genetic risk and family perspectives on clinical genetic testing in children of African ancestry with nephrotic syndrome in Ontario
探讨安大略省非洲血统肾病综合征儿童的 APOL1 遗传风险和家庭视角对临床基因检测的影响
  • 批准号:
    486524
  • 财政年份:
    2022
  • 资助金额:
    $ 1.28万
  • 项目类别:
    Studentship Programs
Ultrabright Plasmonic-Fluor Nanosensor-Enabled Noninvasive Management of Pediatric Nephrotic Syndrome
超亮等离子体荧光纳米传感器支持小儿肾病综合征的无创治疗
  • 批准号:
    10593497
  • 财政年份:
    2022
  • 资助金额:
    $ 1.28万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了